DCT
1:15-cv-13099
Purdue Pharma LP v. Collegium Pharmaceutical Inc
Key Events
Amended Complaint
Table of Contents
complaint Intelligence
I. Executive Summary and Procedural Information
- Parties & Counsel:
- Plaintiff: Knoa Pharma LLC, and Knoa Pharmaceuticals LLC (Delaware)
- Defendant: Collegium Pharmaceutical, Inc. (Virginia)
- Plaintiff's Counsel: Jones Day
- Case Identification: 1:15-cv-13099, D. Mass., 09/01/2026
- Venue Allegations: Venue is based on Defendant's principal place of business being located in the District of Massachusetts, along with its business of preparing, marketing, and distributing pharmaceuticals within the district.
- Core Dispute: Plaintiff alleges that Defendant's Xtampza® ER, an extended-release oxycodone product, infringes three patents related to high-purity oxycodone compositions and the processes for manufacturing them.
- Technical Context: The technology relates to pharmaceutical preparations of the opioid analgesic oxycodone, with a specific focus on methods to reduce the presence of certain impurities, particularly 14-hydroxycodeinone.
- Key Procedural History: This amended complaint is part of a long-running litigation initiated in 2015. Previous infringement claims on other patents have been dismissed. Notably, certain claims of one patent-in-suit (the '933 patent) were found invalid as obvious in separate litigation against an unrelated party. The complaint also notes that all three patents-in-suit have expired, limiting the claims to damages for past infringement.
Case Timeline
| Date | Event |
|---|---|
| 2004-03-30 | Earliest Priority Date for '933, '434, and '098 Patents |
| 2015-07-07 | U.S. Patent No. 9,073,933 Issues |
| 2015-09-23 | Collegium sends Paragraph IV notice letter for '933 patent |
| 2015-11-06 | Initial suit filed alleging infringement of the '933 patent |
| 2016-04-26 | FDA approves Collegium's New Drug Application for Xtampza® ER |
| 2016-06-20 | Collegium announces commercial launch of Xtampza® ER |
| 2019-09-10 | U.S. Patent No. 10,407,434 Issues |
| 2022-02-01 | U.S. Patent No. 11,236,098 Issues |
| 2023-04-11 | Claims 3 and 11 of the '933 patent found invalid in separate litigation |
| 2026-09-01 | Amended and Supplemental Complaint Filed |
II. Technology and Patent(s)-in-Suit Analysis
U.S. Patent No. 9,073,933 - "OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE"
- Patent Identification: U.S. Patent No. 9073933, "OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE," issued July 7, 2015 Compl. ¶11
The Invention Explained
- Problem Addressed: The patent's background section states that commercially available oxycodone hydrochloride active pharmaceutical ingredient (API) and products made by known procedures contain an impurity, 14-hydroxycodeinone, at levels greater than 100 parts per million (ppm) '933 Patent, col. 1:26-30
- The Patented Solution: The invention is a purified oxycodone hydrochloride composition defined by its low level of the 14-hydroxycodeinone impurity (less than 25 ppm) and the presence of another related compound, 8α,14-dihydroxy-7,8-dihydrocodeinone '933 Patent, abstract '933 Patent, col. 2:48-52 The claims are directed to the chemical composition itself, characterized by this specific purity profile.
- Technical Importance: Reducing levels of impurities, particularly alpha, beta unsaturated ketones like 14-hydroxycodeinone which can be genotoxic, is a critical goal in pharmaceutical manufacturing to enhance drug safety and meet regulatory standards.
Key Claims at a Glance
- The complaint asserts claims including dependent claim 4 and independent claim 16 with its dependent claim 17 Compl. ¶22
- Essential elements of Independent Claim 1 (basis for asserted claim 4):
- An oxycodone hydrochloride composition which comprises
- at least 95% oxycodone hydrochloride,
- 8α,14-dihydroxy-7,8-dihydrocodeinone, and
- less than 25 ppm of 14-hydroxycodeinone Compl. ¶23
- Essential elements of Independent Claim 16:
- An oxycodone hydrochloride composition which comprises
- at least 95% oxycodone hydrochloride,
- 8α,14-dihydroxy-7,8-dihydrocodeinone,
- less than 5 ppm of codeinone, and
- less than 25 ppm of 14-hydroxycodeinone Compl. ¶25
U.S. Patent No. 10,407,434 - "PROCESS FOR PREPARING OXYCODONE COMPOSITIONS"
- Patent Identification: U.S. Patent No. 10407434, "PROCESS FOR PREPARING OXYCODONE COMPOSITIONS," issued September 10, 2019 Compl. ¶13
The Invention Explained
- Problem Addressed: The synthesis of oxycodone from thebaine creates an impurity, 8,14-dihydroxy-7,8-dihydrocodeinone, which is carried through the process and can dehydrate under acidic conditions to form 14-hydroxycodeinone in the final product '434 Patent, col. 1:15-24
- The Patented Solution: The patent discloses a multi-step purification process to remove the 8,14-dihydroxy-7,8-dihydrocodeinone impurity from an oxycodone free base or HCl salt '434 Patent, abstract The process involves (i) a reduction step (e.g., hydrogenation), followed by (ii) dissolving in a recrystallization solvent, (iii) cooling to precipitate the purified product, and (iv) recovering the product '434 Patent, claim 1 The patent's Figure 1 provides a reaction scheme showing the creation of this impurity and its relationship to the final product '434 Patent, Fig. 1
- Technical Importance: This process provides a specific method for achieving the high-purity oxycodone composition that is the subject of related patents in the family.
Key Claims at a Glance
- The complaint asserts claims 2, 14, 17, and 19, all of which depend from independent claim 1 Compl. ¶42
- Essential elements of Independent Claim 1:
- A process of purifying oxycodone free base or oxycodone HCl that contains 8α,14-dihydroxy-7,8-dihydrocodeinone or HCl salt thereof, said process comprising:
- (i) reducing the amount of 8α,14-dihydroxy-7,8-dihydrocodeinone or HCl salt thereof in the oxycodone free base or oxycodone HCl;
- (ii) dissolving the resultant oxycodone free base or oxycodone HCl from step (i) in a suitable recrystallization solvent;
- (iii) cooling the recrystallization solvent to precipitate purified oxycodone free base or oxycodone HCl; and
- (iv) recovering the purified oxycodone free base or oxycodone HCl Compl. ¶43
U.S. Patent No. 11,236,098 - "PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE"
- Patent Identification: U.S. Patent No. 11236098, "PROCESS FOR PREPARING OXYCODONE HYDROCHLORIDE HAVING LESS THAN 25 PPM 14-HYDROXYCODEINONE," issued February 1, 2022 Compl. ¶12
- Technology Synopsis: This patent claims an oral dosage form, rather than just the API or a manufacturing process. It describes a formulation comprising oxycodone and the impurity 8α,14-dihydroxy-7,8-dihydrocodeinone within a sustained release matrix '098 Patent, abstract The key limitation is that the ratio of the impurity to oxycodone is 0.04% or less, and the matrix must contain two or more hydrophobic materials '098 Patent, claim 1
- Asserted Claims: Claims 1, 2-10, 11, 12-16, 17, and 18-22 are asserted, including independent claim 1 Compl. ¶90
- Accused Features: The complaint alleges that Xtampza® ER is an oral dosage form containing oxycodone in a sustained release matrix comprising hydrophobic materials (e.g., beeswax, carnauba wax, myristic acid) and that it meets the claimed low ratio of the impurity to oxycodone Compl. ¶¶110-111
III. The Accused Instrumentality
Product Identification
- The accused products are Collegium's Xtampza® ER oxycodone extended release capsules, available in 9 mg, 13.5 mg, 18 mg, 27 mg, and 36 mg dosage strengths Compl. ¶1
Functionality and Market Context
- The complaint describes Xtampza® ER as an oral, extended-release opioid formulation for the treatment of pain Compl. ¶38 Compl. ¶40 The product is alleged to consist of microspheres containing oxycodone base along with hydrophobic materials such as myristic acid, yellow beeswax, and carnauba wax, which form a sustained-release matrix Compl. ¶91 Compl. ¶110
- The complaint alleges that Xtampza® ER directly competes with Knoa's own OxyContin® product and has harmed Knoa by taking its preferred position on drug formularies of major health insurers Compl. ¶¶38-40
No probative visual evidence provided in complaint.
IV. Analysis of Infringement Allegations
'933 Patent Infringement Allegations
| Claim Element (from Independent Claim 16) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| An oxycodone hydrochloride composition which comprises at least 95% oxycodone hydrochloride, 8α,14-dihydroxy-7,8-dihydrocodeinone... | The complaint alleges on information and belief that the accused Collegium NDA Products are covered by the claims and thus embody this composition. | ¶22 | col. 2:48-52 |
| ...less than 5 ppm of codeinone, and less than 25 ppm of 14-hydroxycodeinone. | The complaint alleges that analysis of the Collegium NDA Products, detailed in Preliminary Infringement Contentions, shows they meet these specific impurity limits. | ¶27 | col. 2:48-52 |
- Identified Points of Contention:
- Evidentiary Question: A primary issue will be evidentiary: what proof, based on chemical analysis of commercially sold Xtampza® ER products, can Knoa provide to establish that the products consistently contain "8α,14-dihydroxy-7,8-dihydrocodeinone" while also meeting the specific "less than X ppm" limits for both "codeinone" and "14-hydroxycodeinone" as required by the claim?
- Validity Question: As claims 3 and 11 of the '933 patent were invalidated as obvious in the Accord I Action Compl. p. 2, a key question is whether the asserted claims, which relate to similar subject matter, can withstand a comparable invalidity challenge.
'434 Patent Infringement Allegations
| Claim Element (from Independent Claim 1) | Alleged Infringing Functionality | Complaint Citation | Patent Citation |
|---|---|---|---|
| A process of purifying oxycodone free base or oxycodone HCl that contains 8α,14-dihydroxy-7,8-dihydrocodeinone... | The complaint alleges under 35 U.S.C. § 271(g) that the oxycodone base used in the Collegium NDA Products is made by an infringing process. | ¶52; ¶73 | col. 1:15-30 |
| (i) reducing the amount of 8α,14-dihydroxy-7,8-dihydrocodeinone or HCl salt thereof in the oxycodone free base or oxycodone HCl; | The complaint alleges, based on documents from a supplier (Noramco), that the manufacturer performs this reduction step. | ¶74 | col. 7:15-18 |
| (ii) dissolving the resultant oxycodone free base or oxycodone HCl from step (i) in a suitable recrystallization solvent; (iii) cooling the recrystallization solvent to precipitate purified oxycodone free base or oxycodone HCl; and (iv) recovering the purified oxycodone free base or oxycodone HCl. | The complaint alleges that the supplier, Noramco, performs all steps of the claimed process. The heavily redacted sections appear to contain the specific evidence for these steps. | ¶53; ¶74 | col. 7:1-8:24 |
- Identified Points of Contention:
- Proof of Process Question: Infringement is alleged under § 271(g), which requires proving that the oxycodone base used by Collegium is made by the patented process. A central question will be whether Knoa can produce sufficient evidence, likely through discovery from third-party manufacturers like Noramco and Patheon, to prove that every step of the claimed process is practiced.
- "Materially Changed" Defense Question: Section 271(g) provides a defense if the product made by the patented process is "materially changed by subsequent processes." The complaint preemptively alleges the oxycodone base is not materially changed by formulation into the final product Compl. ¶76 A key legal and factual question will be whether the formulation of the purified API into a complex, multi-ingredient, extended-release microsphere constitutes a "material change" that would absolve Collegium of liability.
V. Key Claim Terms for Construction
For the '933 Patent
- The Term: "composition which comprises"
- Context and Importance: This term from independent claims 1 and 16 is fundamental to defining the scope of the invention. Practitioners may focus on this term because its construction determines whether the claim is limited to a purified Active Pharmaceutical Ingredient (API) or if it extends to a finished drug product that includes the API along with numerous excipients. The infringement allegation is against the final Xtampza® ER drug product Compl. ¶22
- Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The use of the open-ended transition word "comprises" suggests the composition can include other, unrecited elements, such as the excipients found in a final dosage form.
- Evidence for a Narrower Interpretation: The patent specification repeatedly refers to "oxycodone hydrochloride API" when discussing the invention, which could support an argument that the claims are directed to the purified bulk chemical substance itself, not the final drug product containing it '933 Patent, col. 1:21-26
For the '434 Patent
- The Term: "reducing the amount of"
- Context and Importance: This phrase defines the first and critical step of the process claim 1. Practitioners may focus on this term because the infringement analysis will hinge on whether the purification method used by Collegium's API supplier performs an action that falls within the scope of this term.
- Intrinsic Evidence for Interpretation:
- Evidence for a Broader Interpretation: The plain meaning of "reducing" is broad and could be argued to encompass any purification technique-chemical or physical-that lowers the concentration of the specified impurity.
- Evidence for a Narrower Interpretation: The specification provides specific examples of how to perform this step, focusing exclusively on chemical hydrogenation '434 Patent, col. 7:4-8:24 A defendant might argue that the term should be limited to the hydrogenation process disclosed, and that other purification methods (e.g., chromatography) would not constitute "reducing the amount of" in the context of the patent.
VI. Other Allegations
- Indirect Infringement: For all three patents, the complaint alleges induced infringement based on Collegium's product labeling and instructions, which allegedly direct healthcare providers and patients to use the infringing products Compl. ¶33 Compl. ¶79 Compl. ¶115 For the '434 process patent, inducement is also alleged based on Collegium providing specifications to its contract manufacturers (e.g., Patheon, Noramco) that cause them to practice the patented process Compl. ¶¶81-84 Contributory infringement is also pled, based on the products being a material part of the invention with no substantial non-infringing uses Compl. ¶35 Compl. ¶117
- Willful Infringement: The complaint alleges willful infringement for all patents-in-suit Compl. ¶36 Compl. ¶86 Compl. ¶118 The basis for this allegation includes alleged pre-suit knowledge of the '933 and '434 patents from a Paragraph IV notice letter sent in 2015 and the extensive litigation history between the parties Compl. ¶30 Compl. ¶33 Compl. ¶50 For the '098 patent, knowledge is alleged from the date of its issuance Compl. ¶112 The complaint further alleges that Collegium continued its infringing conduct post-suit and lacked a good-faith basis for non-infringement or invalidity Compl. ¶37 Compl. ¶87 Compl. ¶119
VII. Analyst's Conclusion: Key Questions for the Case
- Evidentiary Sufficiency: A core issue will be one of evidentiary proof: can Knoa produce sufficient, consistent chemical analysis from commercial samples of Xtampza® ER to prove that the final product meets the precise quantitative impurity thresholds and compositional elements required by the '933 and '098 patents?
- Process Infringement and the § 271(g) "Materially Changed" Defense: The case will likely turn on a key question of process infringement: first, can Knoa prove that Collegium's third-party API supplier practices every step of the '434 patent's purification process, and second, if infringement is shown, does the subsequent formulation of the API into extended-release microspheres constitute a "material change" to the product, providing a statutory defense to infringement under 35 U.S.C. § 271(g)?
- Pervasive Invalidity Risk: Given that related claims in the '933 patent have already been invalidated for obviousness in separate litigation, a central question for the entire case will be one of patent validity: can the asserted claims across all three patents-which protect overlapping aspects of the same core technology-withstand similar invalidity challenges, or are they likewise vulnerable?
Analysis metadata